NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013

NeuroVive consolidates positioning as leading mitochondrial medicine company
Twelve months (1 Jan. 2013 – 31 Dec. 2013)

  · Net revenues were SEK 5,335,000 (0) and other operating income was SEK
1,598,000 (1,328,000).
  · Loss before tax was SEK -22,126,000 (-15,903,000).
  · Earnings per share* were SEK -1.17 (-0.85).
  · Diluted earnings per share** were SEK -1.17 (-0.85).

Fourth quarter (1 Oct. 2013 – 31 Dec. 2013)

  · Net revenues were SEK 0 (0) and other operating income was SEK 12 (808,000).
  · Loss before tax was SEK -9,169,000 (-5,148,000).
  · Earnings per share* were SEK -0.45 (-0.25).
  · Diluted earnings per share** were SEK-0.45 (-0.25).

* Profit/loss for the period divided by the average number of shares before
dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after
dilution at the end of the period.

Business highlights 2013

First Quarter

  · In March, NeuroVive acquired a portfolio of new cyclophilin inhibitors and
the associated intellectual property from UK biotech enterprise Biotica Ltd.

  · On 22 March, NeuroVive reported that over 600 patients had been enrolled in
the clinical phase III multi-center trial (CIRCUS), which is evaluating the
effects of CicloMulsion® on treating reperfusion injury after stenting
coincident with myocardial infarction.

Second Quarter

  · 10th of April, NeuroVive had its IPO on NASDAQ OMX Small Cap, with stock
symbol NVP.

  · Patient 700 of totally 972 has been enrolled to its multinational phase III
trial on the company’s pharmaceutical CicloMulsion® (CIRCUS trial) or treating
reperfusion injury in myocardial infarction.

  · First patient has been enrolled to a clinical phase IIa trial on the
company’s pharmaceutical NeuroSTAT® for treating traumatic brain damage. This
trial covers a total of 20 patients and is being conducted at the neurology
clinic of the Danish National Hospital in Copenhagen.

  · In June, NeuroVive signed a collaboration agreement with Isomerase
Therapeutics to develop the molecules the company acquired from Biotica Ltd. in
March 2013. The focus of this partnership is cell protection in traumatic brain
damage, heart attack and in the new product segment of anti-viral indications in
the form of a new product designated NVP018/BC556.

  · NeuroVive’s subsidiary NeuroVive Pharmaceutical Asia Ltd. received SEK 5.3
m(RMB 5 m) as a first milestone payment from NeuroVive’s collaboration partner
in China, Sihuan Pharmaceutical.

Third Quarter

  · Over 800 of the 972 patients have been enrolled in the multinational phase
III trial on the company’s pharmaceutical CicloMulsion® (CIRCUS trial) to treat
reperfusion injury coincident with myocardial infarction.

  · With its collaboration partner Sihuan, NeuroVive participated in the 18th
Army Neurosurgery Annual Conference in Beijing, China.

Fourth Quarter

  · Over 900 of the 972 patients have been enrolled in the multinational phase
III trial on the company’s pharmaceuticals CicloMulsion® (CIRCUS trial) to treat
reperfusion injury coincident with myocardial infarction.

  · Catharina Jz Johansson appointed as new CFO and takes up position on 1
December 2013.

  · EGM resolves on private placement and rights issue totaling approximately
SEK 111 m, plus a SEK 10 m overallocation option.

  · NeuroVive completes a SEK 35 m private placement in December.

Post balance sheet events

  · Extended partnership agreement with InVentiv Health to prepare for upcoming
market launch CicloMulsion®

  · On 31 January, NeuroVive announces its rights issue is 270% oversubscribed.
The Board of Directors announces its decision to fully exercise its
overallocation option at the same time. The rights issue raises approximately
SEK 75.8 m for NeuroVive and the overallocation option adds a further SEK 10.0
m. This means that NeuroVive raises a total of approximately SEK 85.8 m before
issue expenses.

  · NeuroVive treats final patient in European phase III trial on CicloMulsion®

Read the Year-End Report attached below

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this news release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 08:30 CEST on
19 January 2014.